Nutex Health (NASDAQ:NUTX) Upgraded by Zacks Research to Hold Rating

Nutex Health (NASDAQ:NUTX) was upgraded by research analysts at Zacks Research to a “hold” rating in a report released on Monday,Zacks.com reports.

A number of other equities research analysts also recently commented on NUTX. B. Riley Financial initiated coverage on Nutex Health in a report on Friday, June 26th. They issued a “buy” rating and a $290.00 target price for the company. Lake Street Capital began coverage on shares of Nutex Health in a research note on Tuesday, June 2nd. They issued a “buy” rating and a $235.00 price objective for the company. Weiss Ratings upgraded shares of Nutex Health from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, May 4th. Finally, Wall Street Zen upgraded shares of Nutex Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Three equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $243.33.

Nutex Health Stock Performance

NASDAQ NUTX opened at $170.89 on Monday. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 13.21 and a beta of 0.26. The business’s 50 day moving average is $131.86 and its two-hundred day moving average is $129.94. Nutex Health has a 12-month low of $77.21 and a 12-month high of $193.07. The company has a current ratio of 3.14, a quick ratio of 3.12 and a debt-to-equity ratio of 0.66.

Nutex Health (NASDAQ:NUTX) last posted its quarterly earnings results on Thursday, April 30th. The company reported $6.52 EPS for the quarter, beating the consensus estimate of $3.99 by $2.53. Nutex Health had a return on equity of 23.50% and a net margin of 10.95%.The business had revenue of $216.49 million during the quarter, compared to analysts’ expectations of $227.80 million. Research analysts expect that Nutex Health will post 22.72 EPS for the current year.

Hedge Funds Weigh In On Nutex Health

Hedge funds have recently added to or reduced their stakes in the business. Islay Capital Management LLC purchased a new stake in shares of Nutex Health in the fourth quarter valued at about $34,000. BNP Paribas Financial Markets raised its position in shares of Nutex Health by 966.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 320 shares of the company’s stock worth $40,000 after purchasing an additional 290 shares during the last quarter. Royal Bank of Canada raised its position in shares of Nutex Health by 752.4% during the 4th quarter. Royal Bank of Canada now owns 358 shares of the company’s stock worth $59,000 after purchasing an additional 316 shares during the last quarter. Osaic Holdings Inc. lifted its stake in Nutex Health by 280.3% in the 4th quarter. Osaic Holdings Inc. now owns 810 shares of the company’s stock valued at $133,000 after buying an additional 597 shares in the last quarter. Finally, EverSource Wealth Advisors LLC purchased a new stake in Nutex Health in the 1st quarter valued at approximately $83,000. 5.32% of the stock is currently owned by hedge funds and other institutional investors.

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.